Ginger in patients with active ulcerative colitis: a study protocol for a randomized controlled trial.

<bold>Background: </bold>As a lifetime disorder, ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that affects quality of life and also demands long-term interventions. In spite of considerable side effects and sometimes restricted uses, efficient medications are available for UC treatment. Some in vitro and in vivo examinations have correspondingly introduced ginger and its active components with antioxidant, anti-inflammatory, and anti-ulcerative properties. Therefore, this trial aims to evaluate the effect of ginger supplementation on patients with active UC.<bold>Methods: </bold>This study will be a 12-week, double-blind, parallel-group, randomized, controlled trial (RCT) in which 44 patients will be allocated to ginger and placebo groups receiving basic routine treatments plus ginger or placebo capsules, respectively. The primary outcomes are inflammatory markers (TNF-α and hs-CRP) and total antioxidant capacity.<bold>Discussion: </bold>The findings of this trial will provide evidence on the effect of ginger on patients with active UC.<bold>Trial Registration: </bold>Iranian Registry of Clinical Trials, IRCT20190129042552N1. Registered on 21 June 2019. [ABSTRACT FROM AUTHOR]